Publications dans lesquelles il/elle collabore avec Juan Berenguer Berenguer (12)

2020

  1. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 628-639

2017

  1. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 10, pp. 2869-2878

  2. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 6, pp. 471-478

  2. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection

    Liver International, Vol. 36, Núm. 9, pp. 1258-1266

  3. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1

  4. Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfected patients on Hepatitis C Virus therapy

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 3, pp. 226-231

2015

  1. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients

    Current Opinion in HIV and AIDS, Vol. 10, Núm. 5, pp. 309-315

2014

  1. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 2, pp. 113-119

  2. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2010

  1. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study

    The Lancet, Vol. 376, Núm. 9738, pp. 340-345

2006

  1. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: Results from a large multicenter observational cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 41, Núm. 2, pp. 154-159